Table 2.

The most common adverse events (AEs) during sunitinib therapy in the entire analyzed group of GIST patients

	Any grade		Grade 3/4
AEs	n	%	N	%
Any treatment-related AE	127	92.7	43	31.4
Fatigue	89	65	12	8.7
Diarrhea	37	28	4	2.9
Hand-foot syndrome	55	40	3	2.2
Decreased appetite/dysgeusia	25	18.2	0	0
Mucositis	35	25.5	2	1.5
Hypertension	59	43	4	2.9
Neutropenia	49	36	7	5.1
Anemia	51	37	8	5.8
Skin/hair discoloration	41	30	0	0
Dyspepsia	43	31.4	0	0
Thrombocytopenia	18	13.1	3	2.2
Hypothyroidism	42	31	2	1.5